AcquisitionsJun 22, 2026, 04:06 PM
Centessa Acquisition by Lilly Approved by UK Court for $7.8B
AI Summary
Centessa Pharmaceuticals announced that the High Court of Justice of England and Wales has approved the proposed acquisition by Eli Lilly and Company. The transaction is valued at approximately $7.8 billion, with Centessa shareholders receiving $38.00 in cash per share plus one non-transferable contingent value right (CVR) entitling them to up to an aggregate of $9.00 per share. The closing of the transaction is expected to occur on June 24, 2026, with the last day of trading for Centessa ADSs on Nasdaq anticipated to be June 23, 2026.
Key Highlights
- UK High Court approved Eli Lilly's acquisition of Centessa Pharmaceuticals.
- Transaction valued at approximately $7.8 billion.
- Shareholders to receive $38.00 in cash per share.
- Shareholders also receive one CVR for up to $9.00 per share.
- Scheme of arrangement sanctioned by the Court.
- Closing expected on June 24, 2026.
- Last day of trading for Centessa ADSs on Nasdaq expected June 23, 2026.
Price Impact
More from CNTA